LFG
EWTX icon

Larson Financial Group’s Edgewise Therapeutics EWTX Stock Holding History

Larson Financial Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.31K Buy
180
+4
+2% +$138 ﹤0.01% 2587
2026
Q1 		$5.54K Sell
176
-49
-22% -$1.41K ﹤0.01% 2551
2025
Q4 		$5.58K Buy
225
+90
+67% +$1.81K ﹤0.01% 2411
2025
Q3 		$2.19K Buy
+135
New +$1.92K ﹤0.01% 2667

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Larson Financial Group's EWTX Position: Q2 2026 in Review

Larson Financial Group increased its Edgewise Therapeutics (EWTX) stake by 2.3% in Q2 2026, buying an estimated $138 and bringing the position to 180 shares worth $7.31K. The position accounts for ﹤0.01% of the portfolio, ranked #2587.

Larson Financial Group first reported a position in EWTX in Q3 2025 and has held it in 4 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Larson Financial Group held 180 shares of Edgewise Therapeutics worth $7.31K as of Q2 2026.
  • Larson Financial Group bought 4 Edgewise Therapeutics shares in Q2 2026, an estimated $138.
  • Edgewise Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2587 holding.
  • Larson Financial Group first reported a position in Edgewise Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.